Abimufloxacin

Abimufloxacin (OPS-2071) exhibits potent broad-spectrum in vitro antibacterial activity against clinically isolated enteropathogenic Gram-positive bacteria (MSSA, MRSA, B. cereus) and Gram-negative bacteria (C. jejuni, E. coli, S. enterica, Shigella spp., Y. enterocolitica, A. hydrophila/sp., K. oxytoca, V. fluvialis, P. shigelloides). Compared with existing quinolone drugs, it shows stronger activity against MRSA and quinolone-resistant C. jejuni^[1].
Abimufloxacin potently inhibits wild-type and quinolone-resistant mutant DNA gyrases of S. aureus and C. jejuni, while exhibiting comparable activity against E. coli DNA gyrase and topoisomerase IV^[1].
Abimufloxacin (4‑64 × MIC; 18‑48 h) shows no detectable spontaneous resistance in Staphylococcus aureus ATCC 29231 and Escherichia coli ATCC 25922 at concentrations up to 64 × MIC; meanwhile, it confers a markedly lower spontaneous resistance rate for Campylobacter jejuni ATCC 33560 at 16 × MIC compared with existing quinolone drugs^[1].
Abimufloxacin exhibits lower MPC against Staphylococcus aureus ATCC 29231 and Campylobacter jejuni ATCC 33560 than existing quinolone drugs, while its MPC against Escherichia coli ATCC 25922 is slightly higher than that of existing quinolone drugs, which indicates a lower risk of selecting drug‑resistant mutants in Gram‑positive bacteria and Campylobacter jejuni strains^[1].
Abimufloxacin exhibits in vitro antibacterial activity against bacteria associated with inflammatory bowel disease (IBD), with an MIC_s range of 0.015 to 0.5 mg/mL^[2].

Abimufloxacin (OPS-2071) inhibits TNF‑α production in human peripheral blood cells and THP‑1 macrophages in a dose‑dependent manner, suppresses the activation, proliferation and cytokine production of human peripheral blood mononuclear cells, and its effect at high concentrations is comparable to that of Prednisolone (HY‑17463)^[2].